REG - hVIVO plc - Director's Dealings <Origin Href="QuoteRef">HVO.L</Origin>

hVIVOAnnouncement

15/07/2015 17:33

RNS Number : 1260N
hVIVO plc
14 May 2015
For immediate release 7.00am: 14 May 2015
HVIVO PLC
("hVIVO" or the "Company")
Director's Dealings
hVIVO plc (AIM: HVO), the pioneer of human challenge models of disease, was notified on 13 May 2015 that the following Director's dealings took place on 13 May 2015: 
 Graham Yeatman, a Director of the Company, transferred a total of 60,000 ordinary shares of 5 pence each in the Company ("Ordinary Shares") to his spouse, Sonja Yeatman, for nil consideration.
 Graham Yeatman sold a total of 3,701 Ordinary Shares held outside his individual savings account ("ISA") at a price of 300.00 pence per Ordinary Share. Mr Yeatman then purchased 3,701 Ordinary Shares inside his ISA at a price of 300.80 pence per Ordinary Share.
 Sonja Yeatman sold a total of 3,701 Ordinary Shares held outside her ISA at a price of 300.00 pence per Ordinary Share. Mrs Yeatman then purchased 3,701 Ordinary Shares inside her ISA at a price of 300.80 pence per Ordinary Share.
Following these transactions, there has been no change to the total beneficial holding of Mr Yeatman, and he continues to be interested in 185,200 Ordinary Shares (which represents approximately 0.3% of the Company's issued share capital). 62,700 Ordinary Shares are registered in the name of Mr Yeatman and 122,500 Ordinary Shares are registered in the name of Mrs Yeatman and their children.
For further information please contact:
hVIVO plc+44 207 756 1300
Kym Denny (Chief Executive Officer)
Graham Yeatman (Chief Financial & Business Officer) 
Media Enquiries+44 203 021 3933 / +44 7854 979 420
Colin Paterson (Director of Marketing, Communication and Public Relations)
 
Numis Securities Limited  +44 207 260 1000 
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
hVIVO plc ("hVIVO") is a life sciences company pioneering a technology platform of human disease models to accelerate drug development and discovery in respiratory and infectious diseases. Based in the UK, hVIVO has conducted over 40 clinical studies, involving more than 1950 volunteers for a range of leading industry, governmental and academic clients.

This information is provided by RNS
The company news service from the London Stock Exchange
  END
RDSGGUCUAUPAPPW